Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials

Abstract Background Relebactam is a new inhibitor of class A and class C β-lactamases. The FDA has approved combining IMI/CS/REL to treat some infectious diseases. This study systematically reviews the efficacy and safety of IMI/CS/REL based on existing clinical trials so as to provide a reference f...

Full description

Bibliographic Details
Published in:	BMC Infectious Diseases
Main Authors:	Wenjuan Lei, Yan Duan, Mingyan Xin, Min Tian, Jia Xu
Format:	Article
Language:	English
Published:	BMC 2025-09-01
Subjects:	Imipenem/cilastatin/relebactam Efficacy Safety Carbapenem resistant gram-negative bacteria
Online Access:	https://doi.org/10.1186/s12879-025-11499-w

Similar Items

Safety Profiles of Polymyxins, Aminoglycosides, and Imipenem/Cilastatin/Relebactam (IMI/REL) in the Treatment of Gram-Negative Infections: A Literature Review
by: Hannah Collings, et al.
Published: (2026-04-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
by: Qingxin Yang, et al.
Published: (2023-12-01)

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
by: Ryan K. Shields, et al.
Published: (2024-06-01)

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience
by: Cristiana Leanza, et al.
Published: (2024-07-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
by: Jaesh Naik, et al.
Published: (2023-01-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
by: Pasquale Sansone, et al.
Published: (2024-05-01)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
by: Dai Kurihara, et al.
Published: (2022-04-01)

Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis
by: Reza Abniki, MS, et al.
Published: (2024-01-01)

Development of a novel LC-MS/MS method for concurrent determination of imipenem, relebactam, and cilastatin in human serum, urine and peritoneal drainage fluid
by: Xiaoyu Yang, et al.
Published: (2026-04-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
by: Paul Laffont-Lozes, et al.
Published: (2024-10-01)

SAPD PERİTONİTİNİN TEDAVİSİNDE IMIPENEM/CILASTATIN
by: Arif KAPUAGASI, et al.
Published: (2019-03-01)

Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
by: Tsung-Ying Yang, et al.
Published: (2022-02-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
by: Hiroki Nakamura, et al.
Published: (2024-03-01)

Activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae and the possible role of Ompk36 mutation in determining resistance: an Italian retrospective analysis
by: Emanuele Palomba, et al.
Published: (2025-04-01)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021-09-01)

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam
by: Peiyao Jia, et al.
Published: (2025-09-01)

Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR <i>Klebsiella pneumoniae</i> Sternal Infection Complicated by Bacteremia
by: Luca Pipitò, et al.
Published: (2025-10-01)

Integrative greenness, blueness and whiteness determination of analytical RP-HPLC method for identifying Imipenem, Cilastatin and Relebactam in combined tablet form followed by forced degradation studies
by: Revathy Sundara Moorthy, et al.
Published: (2024-12-01)

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
by: Peng Jia, et al.
Published: (2025-02-01)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
by: Katherine Young, et al.
Published: (2019-07-01)

In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer
by: Kenneth V.I. Rolston, et al.
Published: (2022-06-01)

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility
by: Shawn Freed, Jr, et al.
Published: (2024-11-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
by: Xi You, et al.
Published: (2024-03-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Efficacy and safety of novel carbapenem–β-lactamase inhibitor combinations: Results from phase II and III trials
by: Wei Yu, et al.
Published: (2022-09-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
by: Shakila Baei Lashaki, et al.
Published: (2025-05-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS
by: Ana Candela, et al.
Published: (2025-05-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
by: Sakiko Hiraki, et al.
Published: (2023-03-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
by: Telma de Sousa, et al.
Published: (2023-11-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
by: Takaki Hirano, et al.
Published: (2022-12-01)

A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)
by: Junjie Li, et al.
Published: (2025-04-01)

In vitro activity of imipenem–relebactam against carbapenem-resistant Pseudomonas aeruginosa: correlation with carbapenem MICs and association with β-lactamase classes
by: Aynaa I. Alsharidi, et al.
Published: (2026-05-01)

In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021
by: Amanda Azevedo Bittencourt, et al.
Published: (2025-07-01)

Case Report: Delayed-type hypersensitivity reaction to meropenem in an elderly patient—successful management with imipenem-cilastatin
by: Cuilin He, et al.
Published: (2025-10-01)

Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024
by: Mark G. Wise, et al.
Published: (2026-05-01)

Genicular Artery Embolization with Imipenem/Cilastatin for Pigmented Villonodular Synovitis of the Knee: A Case Report
by: Matteo Cappucci, et al.
Published: (2025-02-01)